北京凯因科技股份有限公司 2024年度募集资金存放与使用情况 鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 景 目 页 次 | 一、北京凯因科技股份有限公司 2024年度募集资金存放与使用情 | | --- | | 1-2 况鉴证报告 | 二、北京凯因科技股份有限公司关于 2024 年度募集资金存放与实 1-7 际使用情况的专项报告 三、事务所执业资质证明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 ...

国泰海通证券股份有限公司 关于北京凯因科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 北京凯因科技股份有限公司（以下简称"凯因科技"或"公司"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规 定，对凯因科技 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 （二）募集资金以前年度使用金额 截至 2024 年 12 月 31 日，公司累计使用募集资金 55,269.57 万元（包括置换 预先投入金额），本年度使用募集资金 4,566.38 万元，募集资金余额为 19,713.31 万元（含利息）。 （三）募集资金本年度使用金额及年末余额 2024 年度，公司使用募集资金 4,566.38 万元。截至 2024 年 12 月 31 日，公 司累计已使用募集资 ...

委托单位：北京凯因科技股份有限公司 审计单位：中汇会计师事务所（特殊普通合伙） 联系电话：010-67892271 关于北京凯因科技股份有限公司 2024年度非经营性资金占用及其他 关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 1、 专项审计报告 2、 附表 目 录 关于北京凯因科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 页 次 一、关于北京凯因科技股份有限公司 2024年度非经营性资金占用 1-2 及其他关联资金往来情况的专项审核说明 二、2024年度非经营性资金占用及其他关联资金往来情况汇总表 1 三、事务所执业资质证明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 ...

国泰海通证券股份有限公司 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为北 京凯因科技股份有限公司（以下简称"凯因科技"、"公司"或"发行人"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就凯因科技使 用暂时闲置募集资金进行现金管理的事项进行了审慎核查，并发表如下核查意 见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京凯因科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕8 号）核准，公司首次公开发行股票 4,246 万股，每股发行价格为人民币 18.98 元，募集资金总额为人民币 80,589.08 万元，扣除各项发行费用后实际募集资金净额为人民币 72,586.61 万元。上述募 集资金到位情况已经中汇事务所（特殊普通合伙）验证，并由其出具中汇会验 [2021]0208 号《验资报告》。 上述募集资金已全部存放 ...

北京凯因科技股份有限公司 审计报告 2024 年度 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel0571-88879999 Fax.0571-88879000 www.zhcpa.cn from 201 合由具有护 您可使用手机"扫一扫"或进入"注册 M | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 1-12 | | (一) 合并资产负债表 | 1-2 | | (二) 合并利润表 | ങ | | (三) 合并现金流量表 | বা | | (四) 合并所有者权益变动表 | 5-6 | | (五) 母公司资产负债表 | 7-8 | | (六) 母公司利润表 | 9 | | (七) 母公司现金流量表 | 10 | | (八) 母公司所有者权益变动表 | 11-12 | 三、财务报表附注 13-108 四、事务所执业资质证明 中国杭州 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 231,594,549.40, representing an increase of 8.90% compared to CNY 212,673,809.18 in the same period last year[3] - Net profit attributable to shareholders was CNY 25,668,499.89, up 15.92% from CNY 22,144,168.59 year-on-year[3] - The basic earnings per share increased to CNY 0.15, reflecting a growth of 15.38% compared to CNY 0.13 in the same period last year[3] - The weighted average return on equity rose to 1.38%, an increase of 0.13 percentage points from the previous year[3] - The total comprehensive income for Q1 2025 was ¥25,457,646.89, compared to ¥24,435,627.84 in Q1 2024, indicating a year-over-year increase of 4.18%[20] Cash Flow - The net cash flow from operating activities improved significantly to CNY 5,867,946.35, compared to a negative cash flow of CNY 21,401,412.37 in the previous year[3] - Cash inflow from operating activities in Q1 2025 was ¥306,415,268.60, compared to ¥254,799,484.90 in Q1 2024, marking a rise of 20.25%[23] - The net cash flow from investing activities was -$6,546,054.13, an improvement from -$41,820,838.82 year-over-year[24] - Cash inflows from investing activities increased to $320,225,602.20, compared to $214,373,286.29 in the previous year[24] - The net cash flow from financing activities was -$4,962,686.72, a decline from a positive cash flow of $53,399,639.61 in the previous year[24] Expenses - Research and development expenses totaled CNY 26,277,546.81, a decrease of 9.58% from CNY 29,061,914.47, with R&D expenses accounting for 11.35% of revenue, down from 13.67%[4] - Total operating costs for Q1 2025 were ¥203,783,050.51, up from ¥191,738,956.41 in Q1 2024, reflecting a year-over-year increase of 6.18%[18] - The company reported a decrease in sales expenses to ¥114,742,965.35 in Q1 2025 from ¥103,972,619.47 in Q1 2024, showing improved cost management[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,520,928,379.89, a decrease of 3.62% from CNY 2,615,625,220.30 at the end of the previous year[4] - Total current assets decreased from CNY 1,860,100,437.22 as of December 31, 2024, to CNY 1,766,807,100.13 as of March 31, 2025, representing a decline of approximately 5.0%[12] - Total liabilities decreased to ¥612,302,223.30 in Q1 2025 from ¥735,327,270.60 in Q1 2024, a reduction of approximately 16.73%[15] - Total equity attributable to shareholders increased to ¥1,875,027,245.21 in Q1 2025 from ¥1,843,247,304.90 in Q1 2024, reflecting a growth of 1.73%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,805[8] - The largest shareholder, Beijing Song'an Investment Management Co., Ltd., held 22.46% of the shares, totaling 38,400,000 shares[8] Inventory and Fixed Assets - Inventory increased from CNY 144,238,608.29 to CNY 156,820,240.98, reflecting an increase of approximately 8.7%[13] - Fixed assets increased from CNY 245,864,224.69 to CNY 423,339,967.97, an increase of approximately 72.2%[13] - The company’s cash outflows for the acquisition of fixed assets and intangible assets were $12,771,656.33, significantly lower than $51,194,125.11 in the prior year[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.23 billion, a decrease of 12.87% compared to ¥1.41 billion in 2023[24]. - Net profit attributable to shareholders for 2024 was approximately ¥142.37 million, an increase of 22.18% from ¥116.52 million in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥136.98 million, up 11.75% from ¥122.58 million in 2023[24]. - The net cash flow from operating activities for 2024 was approximately ¥104.29 million, a decrease of 17.63% compared to ¥126.60 million in 2023[24]. - The total assets at the end of 2024 were approximately ¥2.62 billion, an increase of 6.84% from ¥2.45 billion at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.84 billion, reflecting a growth of 5.10% from ¥1.75 billion at the end of 2023[24]. - The company's operating revenue for 2024 was CNY 1,230.30 million, a decrease of 12.87% compared to 2023, primarily due to price reductions following the implementation of centralized procurement policies for key products[27]. - Basic and diluted earnings per share for 2024 were CNY 0.85, reflecting a year-on-year growth of 21.43%[27]. - The weighted average return on equity increased to 7.93% in 2024, up by 1.12 percentage points from 2023[27]. Dividend Distribution - The company plans to distribute a cash dividend of 3.00 CNY per 10 shares, totaling approximately 50.23 million CNY, which represents 35.28% of the net profit attributable to shareholders[6]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[7]. Corporate Governance - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The board of directors, supervisory board, and senior management confirm the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to maintaining high standards of corporate governance, as evidenced by the stability in its board composition[167]. Research and Development - Research and development expenses accounted for 12.79% of operating revenue in 2024, an increase of 0.57 percentage points compared to the previous year[27]. - The company maintained a high R&D investment, totaling CNY 157.41 million, which accounted for 12.79% of operating revenue, and applied for 9 invention patents during the reporting period[40]. - The company has developed innovative drugs such as the pan-genotype oral drug and interferon α-2 injection, which have been industrialized successfully[44]. - The company has established a multi-target, multi-mechanism R&D pipeline in the field of viral hepatitis treatment, including projects KW-001, KW-027, and KW-040[68]. - The company has a total of 453 intellectual property rights, including 264 granted[65]. Market Strategy - The company follows a "sales-driven production" strategy, adjusting production plans based on market demand and sales forecasts[50]. - The company has established a comprehensive distribution system by collaborating with qualified pharmaceutical distributors across the country[51]. - The company is focused on expanding its product offerings in the pharmaceutical sector, particularly in the treatment of chronic hepatitis C[123]. - The company aims to accelerate the launch of new products and increase market share in 2025, focusing on innovative drug development and sales growth[152]. Regulatory Compliance - The company received an administrative regulatory measure decision from the China Securities Regulatory Commission on December 19, 2024[182]. - The company held meetings to address prior accounting errors and submitted a rectification report as required by the regulatory decision[183]. - The company disclosed corrected financial reports for the first three quarters of 2023 on December 20, 2024[183]. - The company has faced penalties from regulatory bodies in the past three years, necessitating corrective actions[182]. Employee and Management Information - The total compensation for the board members and senior management during the reporting period amounted to CNY 2,386.52 million[168]. - The company has a total of 600 employees, with 383 in the parent company and 217 in major subsidiaries[196]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 21.39 million RMB[179]. - The company has retained key personnel in core technology roles, ensuring continuity in its strategic direction and innovation efforts[169]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of 25% and aiming for $1.875 billion[170]. - The company plans to enhance its core competitiveness by focusing on innovative drug development for hepatitis B functional cure and immune disease prevention[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[170].

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 北京松安投资管理有限公司 | 3840.00 | 22.46 | 不变 | | 中庚价值先锋股票 | 633.45 | 3.71 | 280.37 | | 中庚价值领航混合 | 481.41 | 2.82 | 47.23 | | 易方达基金管理有限公司-社保基金17042组合 | 465.18 | 2.72 | 145.58 | | 毛顺华 | 317.95 | 1.86 | 新进 | | 北京富山湾投资管理中心(有限合伙) | 315.66 | 1.85 | 不变 | | 北京富宁湾投资管理中心(有限合伙) | 311.31 | 1.82 | 不变 | | 中庚价值品质一年持有期混合 | 293.55 | 1.72 | 10.00 | | 易方达新经济混合 | 243.31 | 1.42 | -70.45 | | 易方达科翔混合 | 241.08 | 1.41 | -99.28 | | 较上个报告期退出前十大股东有 | ...

Core Insights - The company reported a revenue of 1.23 billion yuan for 2024, with a net profit of 142 million yuan, marking a year-on-year growth of 22.18% [1] - In Q1 2025, the company achieved a revenue of 232 million yuan, reflecting an 8.90% year-on-year increase, and a net profit of approximately 25.67 million yuan, up 15.92% year-on-year [1] - The company maintained a high R&D investment intensity, with R&D expenditures of 157 million yuan in 2024, accounting for 12.79% of revenue, an increase of 0.57 percentage points year-on-year [1] R&D Progress - The company made significant advancements in several R&D projects during the reporting period, including the completion of Phase III clinical trials for KW-001 and the submission of a drug registration application [1] - KW-045 completed treatment and follow-up for all participants in its Phase IIa clinical trial for pediatric herpes pharyngitis [1] - KW-051 and KW-053 also progressed in their respective clinical trials, with KW-053 receiving approval for Phase II trials [1] Patent Activity - In 2024, the company applied for 9 invention patents and received authorization for 7, bringing the total to 175 applications and 60 authorized patents by the end of the reporting period [2] Capacity and Facility Upgrades - The company is advancing its antibody production base project, which has been included in Beijing's key engineering plans, with the main structure completed [3] - The company is upgrading its oral solid dosage production line and expanding capacity to accommodate future product launches [3] - The company is committed to enhancing its R&D capabilities and technical platform while focusing on innovative drug development and international collaboration [3]